Navigation Links
Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection
Date:1/14/2010

BEDFORD, Ohio, Jan. 14 /PRNewswire/ -- Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce FDA approval for the addition of 100 mg/50 mL Fluconazole Injection to its existing Fluconazole Injection line. This product is AP rated and is equivalent to Diflucan® by Pfizer. Fluconazole Injection is an antifungal agent indicated for oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and is indicated for the prophylaxis of candidiasis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )

"Pharmacists asked, we answered. In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to be the first to offer this unique dosage. Fluconazole Injection 100 mg/50 mL is right-sized for smaller doses, speeding productivity and saving time. This continues to demonstrate our commitment to providing a broad-based portfolio of products," said David Gaugh, Vice President of Bedford Laboratories.

Bedford Laboratories will supply Fluconazole Injection sterile iso-osmotic solution containing 2 mg/mL of fluconazole in glass vials in the following presentations:  Vials containing either 100 mg, 200 mg or 400 mg equivalent of fluconazole. In addition, Bedford Laboratories will supply Fluconazole Injection as a sterile iso-osmotic solution containing 2 mg / mL of fluconazole in 0.9% sodium chloride diluent in the following presentations:  200 mg/100 mL in single-dose PVC flexible containers packaged in cartons containing 10 bags and 400 mg/200 mL in single-dose PVC flexible containers packaged in cartons containing 10 bags.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products offering a broad range of multisource injectables across multiple therapeutic classes. Bedford Laboratories is one of the largest generic injectable pharmaceutical companies in the US.

Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc. For more information on Bedford Laboratories, visit www.bedfordlabs.com.

About Ben Venue Laboratories, Inc.

Ben Venue Laboratories, Inc. was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. BVL has been under contract with the National Cancer Institute since 1967 to develop parenteral dosage forms for many anticancer agents. It has also manufactured various AIDS-specific drugs in conjunction with the NCI. Ben Venue is located in Bedford, Ohio and employs more than 1,300 people.  For more information on Ben Venue Laboratories and current career opportunities, visit www.benvenue.com.

Ben Venue is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim Corporation

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of $17 billion (11.6 billion euro) while spending one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com.

Diflucan® is a registered trademark of Pfizer Inc.

SOURCE Bedford Laboratories

RELATED LINKS
http://www.bedfordlabs.com

'/>"/>

SOURCE Bedford Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
2. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
7. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
8. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
11. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
(Date:2/24/2017)... STOCKHOLM , Feb 24, 2017 ... Nomination Committee,s proposal for a new Board of Directors ... Meeting. The 2016-2017 Nomination Committee comprises representatives of the ... third quarter of 2016 who have accepted a seat ... Board. The composition of the 2016-2017 Nomination Committee was ...
(Date:2/24/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Urinary Incontinence Drugs ... benchmarks in the global Urinary Incontinence market. The research answers ... key drugs marketed for Urinary Incontinence and their clinical attributes? How ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., ... From Not to Hot,” which will begin airing on February 24, 2017. The show ... from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... 2017 , ... Current Meditation , a new meditation ... the U.S. starting this spring. Current Meditation focuses on “meditation for the modern ... Meditation will be the first meditation concept in the U.S. offering franchising opportunities, ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... CALNOC, the ... FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in ... chairman and CEO of the Virginia Mason Health System in Seattle since 2000. In ...
(Date:2/23/2017)... ... 2017 , ... Thomas Vas-Don suffered from severe injury due to ... able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” ... principals of massage, anatomy , trigger points and referral pain patterns . ...
Breaking Medicine News(10 mins):